4 Matching Annotations
  1. Apr 2021
    1. Table 1:Potential treatments

      Blockade of NFkB/TLR4 pathway may also be beneficial due to the SARS-CoV-2 activation of TLR4 https://doi.org/10.1101/2020.12.18.423427

      Anti-viral neuraminidase inhibitors such as Oseltamivir or Zanamivir reduced neutrophil hyper-activation (via inhibition of host neuraminidase) and may present a new targeted therapeutic strategy https://doi.org/10.1101/2020.11.12.379115

      IL-18 blockade may represent a therapeutic option for COVID-19 as it may participate in hyperinflammation and tissue damage https://doi.org/10.1002/jcp.30008

      Increasing evidence that NK cells could be used as therapies for COVID-19 https://doi.org/10.1186/s40164-021-00199-1 as well as evidence for targeting specific mutants of COVID-19 with ‘off-the shelf’ CAR-NK cells https://doi.org/10.1101/2021.01.14.426742

  2. Sep 2020
  3. Aug 2020
    1. Sherrard-Smith, E., Hogan, A. B., Hamlet, A., Watson, O. J., Whittaker, C., Winskill, P., Ali, F., Mohammad, A. B., Uhomoibhi, P., Maikore, I., Ogbulafor, N., Nikau, J., Kont, M. D., Challenger, J. D., Verity, R., Lambert, B., Cairns, M., Rao, B., Baguelin, M., … Churcher, T. S. (2020). The potential public health consequences of COVID-19 on malaria in Africa. Nature Medicine, 1–6. https://doi.org/10.1038/s41591-020-1025-y

  4. Jul 2020
    1. Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm-Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., Guessous, I., Stringhini, S., Pugin, J., Roux-Lombard, P., Fontao, L., Siegrist, C.-A., Eckerle, I., Vuilleumier, N., & Kaiser, L. (2020). Validation of a commercially available SARS-CoV-2 serological immunoassay. Clinical Microbiology and Infection, 0(0). https://doi.org/10.1016/j.cmi.2020.06.024